CompletedPhase 2ACTRN12610000768099

Ginseng extract for patients with moderate Chronic Obstructive Pulmonary Disease (COPD)

The effect of a standardised ginseng extract on the quality of life and respiratory symptoms of patients with moderate chronic obstructive pulmonary disease: a multi-centre, randomised, double-blind, placebo controlled trial

Sponsor

Royal Melbourne Institute of Technology (RMIT) University

Enrollment

168 participants

Start Date

Dec 13, 2010

Study Type

Interventional

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Summary

This study will investigate the safety profile and efficacy of a standardised extract of Panax ginseng with a focus on quality of life improvements in adults with moderate chronic obstructive pulmonary disease. The study is a multi-centre, randomised, double-blind, placebo-controlled clinical trial. The study will consist of three phases: a run in period of 4 weeks, 24 weeks of treatment and 24 weeks of follow-up.

Eligibility

Sex: Both males and femalesMin Age: 40 Yearss

Plain Language Summary

Simplified for easier understanding

This study tests whether a ginseng extract can help improve lung function and quality of life in people with moderate chronic obstructive pulmonary disease (COPD). Former smokers aged 40 and older with moderate COPD who have been stable for at least 4 weeks may be eligible.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Oral Ginseng extract capsules. 100mg/twice a day for a total of 24 weeks.

Locations(1)

VIC, Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12610000768099

Related Trials

Study of Patient With Frequent Exacerbations in Moscow

NCT073077811 location

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

NCT06883305298 locations

Potential of Interface Care Models to Deliver More Appropriate Care to Patients With Acute Medical Illness

NCT075360351 location

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)

NCT06878261268 locations

Somatic Health Screening for Adults in Outpatient Psychiatric Care in Denmark (SomaScreen)

NCT075184461 location